BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

791 related articles for article (PubMed ID: 20427430)

  • 1. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
    Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
    J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers predicting recurrence and progression of ductal carcinoma in situ treated by lumpectomy alone.
    Allred DC
    J Natl Cancer Inst; 2010 May; 102(9):585-7. PubMed ID: 20427432
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy.
    Molinaro AM; Sison JD; Ljung BM; Tlsty TD; Kerlikowske K
    Breast Cancer Res Treat; 2016 Jun; 157(2):351-361. PubMed ID: 27146587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
    Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
    Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy.
    Kerlikowske K; Molinaro A; Cha I; Ljung BM; Ernster VL; Stewart K; Chew K; Moore DH; Waldman F
    J Natl Cancer Inst; 2003 Nov; 95(22):1692-702. PubMed ID: 14625260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ.
    Davis JE; Nemesure B; Mehmood S; Nayi V; Burke S; Brzostek SR; Singh M
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):20-5. PubMed ID: 26317313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative ultrasound radiomics analysis for expression of multiple molecular biomarkers in mass type of breast ductal carcinoma in situ.
    Wu L; Zhao Y; Lin P; Qin H; Liu Y; Wan D; Li X; He Y; Yang H
    BMC Med Imaging; 2021 May; 21(1):84. PubMed ID: 34001017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
    Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
    Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
    [No Abstract]   [Full Text] [Related]  

  • 11. Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast.
    Perez AA; Balabram D; Rocha RM; da Silva Souza Á; Gobbi H
    J Histochem Cytochem; 2015 Jun; 63(6):408-16. PubMed ID: 25711229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
    Yang M; Moriya T; Oguma M; De La Cruz C; Endoh M; Ishida T; Hirakawa H; Orita Y; Ohuchi N; Sasano H
    Pathol Int; 2003 Jul; 53(7):422-8. PubMed ID: 12828606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.
    Rakovitch E; Nofech-Mozes S; Hanna W; Narod S; Thiruchelvam D; Saskin R; Spayne J; Taylor C; Paszat L
    Br J Cancer; 2012 Mar; 106(6):1160-5. PubMed ID: 22361634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.
    Zhou W; Jirström K; Johansson C; Amini RM; Blomqvist C; Agbaje O; Wärnberg F
    BMC Cancer; 2010 Nov; 10():653. PubMed ID: 21118480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
    Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
    PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
    Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S
    Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathological and cell biological factors of ductal carcinoma in situ before and after the introduction of mammographic screening.
    Idvall I; Andersson C; Fallenius G; Ingvar C; Ringberg A; Strand C; Akerman M; Fernö M
    Acta Oncol; 2001; 40(5):653-9. PubMed ID: 11669340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.